{"contentid": 488142, "importid": NaN, "name": "Two in-house drugs expecting approval in 2021, says TOT Biopharm", "introduction": "China\u00e2\u0080\u0099s TOT Biopharm International today announced its financials and provided a review of its clinical milestones and pipeline achievements.", "content": "<p>China&rsquo;s TOT Biopharm International (HK: 1875) today announced its financials and provided a review of its clinical milestones and pipeline achievements.</p>\n<p>Key milestones of pipeline products:<br /><br /> -- TAB008 (anti-VEGF MAb): Phase III clinical results were published. The clinical results show that TAB008 has similar efficacy, safety, immunogenicity and pharmacokinetics profiles with the brand-name formulation of bevacizumab. The new drug application under the new version of the Administrative Measures for Drug Registration was submitted, and was accepted by NMPA [China&rsquo;s regulator]. in September 2020 (Pre-approval registration inspection was completed in January 2021). It is expected to be approved for marketing in 2021.<br /><br /> -- TAA013 (anti-HER2 ADC): It is the first T-DM1 ADC product entering Phase III clinical trial in China. The first participant was enrolled in July 2020. Clinical recruitment is progressing smoothly.<br /><br /> -- TAB014 (anti-VEGF MAb): Phase III clinical trial application (IND) was submitted to the Food and Drug Administration. Upon receiving FDA's approval, it would be exempted from the Phase II clinical trial and would directly carry out Phase III clinical trial (IND authorized by FDA in January 2021, and would directly carry out Phase III clinical trial).<br /><br /> -- TOZ309 (temozolomide capsule): Pre-approval registration inspection was completed, and it is expected to be approved for marketing in the first half of 2021.</p>\n<h2><strong>Achieved multiple targets during the year</strong></h2>\n<p>Dr Liu Jun, chief executive officer and chief scientific officer, said: \"TOT Biopharm has achieved multiple targets during the year, and manifested more prominent competitive and it has gradually formed a trend of coordinated development for R&amp;D and commercial production of innovative drugs. In 2020, our R&amp;D achievements are encouraging! The core product TAB008, TOT Biopharm's independently developed bevacizumab biosimilar, has been submitted new drug application under the new version of the Administrative Measures for Drug Registration, and has been accepted by NMPA. Moreover, ADC drug TAA013 has successfully entered Phase III clinical trial, with a leading position in China in terms of our R&amp;D progress.</p>\n<p>Image: china_credit_depositphotos</p>", "date": "2021-03-24 15:32:00", "meta_title": "Two in-house drugs expecting approval in 2021, says TOT Biopharm", "meta_keywords": "TOT Biopharm, Pipeline, Milestones, Bevacizumab, Temozolomide", "meta_description": "Two in-house drugs expecting approval in 2021, says TOT Biopharm", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-24 15:31:32", "updated": "2021-03-24 15:41:12", "access": NaN, "url": "https://www.thepharmaletter.com/article/two-in-house-drugs-expecting-approval-in-2021-says-tot-biopharm", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "china_credit_depositphotos_large.jpg", "image2id": "china_credit_depositphotos_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biosimilars, Biotechnology", "therapy area_tag": "Oncology", "topic_tag": "Asia Pacific, Focus On, Management, Regulation, Research", "geography_tag": "China", "company_tag": "TOT Pharm", "drug_tag": "bevacizumab, Temozolomide", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-24 15:32:00"}